COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine

Huhn, Gregory; Poorbaugh, Josh; Zhang, Lin; Beasley, Stephanie; Nirula, Ajay; Brothers, Jennifer; Welbel, Sharon F.; Wilson, James M.; Gillani, Sheena; Weber, Kathleen M.; Morack, Ralph; Keckler, Kody; Benschop, Robert J.

doi:10.1371/journal.pone.0273323

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings indicate that various human coronaviruses, including common cold viruses, produce cross-reactive memory T-cells that react to the SARS-CoV-2 virus [ 6 , 8 ]. As for the humoral immune response, antibodies to the virus can also be detected in asymptomatic [ 9 , 10 , 11 ] and symptomatic individuals [ 12 , 13 , 14 ]. Longitudinal studies are being conducted to better understand the link between infection state, host immunity, and disease progression.…”

Section: Introductionmentioning

confidence: 99%

Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients

Souan,

Abdel-Razeq,

Al Zughbieh

et al. 2023

Viruses

View full text Add to dashboard Cite

Objective: The kinetics of immune responses to various SARS-CoV-2 vaccines in cancer patients were investigated. Methods: In total, 57 cancer patients who received BNT162b2-RNA or BBIBP-CorV vaccines were enrolled. Cellular and humoral immunity were assessed at three-time points, before the first vaccine dose and 14–21 days after the first and second doses. Chemiluminescent microparticle immunoassay was used to evaluate SARS-CoV-2 anti-spike IgG response, and QuantiFERON® SARS-CoV-2 kit assessed T-cell response. Results: Data showed that cancer patients’ CD4+ and CD8+ T cell-median IFN-γ secretion of SARS-CoV-2 antigens increased after the first and second vaccine doses (p = 0.027 and p = 0.042). BNT162b2 vaccinees had significantly higher IFN-γ levels to CD4+ and CD8+ T cell epitopes than BBIBP-CorV vaccinees (p = 0.028). There was a positive correlation between IgG antibody titer and T cell response regardless of vaccine type (p < 0.05). Conclusions: This study is one of the first to investigate cellular and humoral immune responses to SARS-CoV-2 immunization in cancer patients on active therapy after each vaccine dose. COVID-19 immunizations helped cancer patients develop an effective immune response. Understanding the cellular and humoral immune response to COVID-19 in cancer patients undergoing active treatment is necessary to improve vaccines and avoid future SARS pandemics.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients

Souan,

Abdel-Razeq,

Al Zughbieh

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort

Simmi¹,

E²,

Adam³

et al. 2022

Insights Clin Cell Immunol

View full text Add to dashboard Cite

Determining the extent of immunity induced by booster doses of COVID-19 vaccinations is crucial for informing recommendations for booster dose regimens as well as constant adjustments of immunization strategies amongst different groups of people within the population. The study involved 31 healthy volunteers (majority were healthcare professionals) who completed either vaccination course with Pfizer or Moderna mRNA vaccines and received a third dose of the vaccine. Here we report results on the evaluation of an antibody response to four different SARS-CoV-2 antigens: RBD, S1, S2 and nucleocapsid prior to third dose and two and four weeks after a booster vaccination. We detected a peak of high titers of antibodies after the third dose with a gradual decline after four weeks. No significant differences were seen between the two vaccines in terms of antibody response. There were no gender discrepancies between the two vaccines. Our results suggest that: third doses are necessary due to the emergence of different SARS-CoV-2 variants and postvaccination antibody testing continues be essential in determining possible standardization of SARS-CoV-2 vaccines regimens.

show abstract

In Silico Protein Structure Analysis for SARS-CoV-2 Vaccines Using Deep Learning

Matsuzaka

Yashiro

2023

BioMedInformatics

View full text Add to dashboard Cite

Protein three-dimensional structural analysis using artificial intelligence is attracting attention in various fields, such as the estimation of vaccine structure and stability. In particular, when using the spike protein in vaccines, the major issues in the construction of SARS-CoV-2 vaccines are their weak abilities to attack the virus and elicit immunity for a short period. Structural information about new viruses is essential for understanding their properties and creating effective vaccines. However, determining the structure of a protein through experiments is a lengthy and laborious process. Therefore, a new computational approach accelerated the elucidation process and made predictions more accurate. Using advanced machine learning technology called deep neural networks, it has become possible to predict protein structures directly from protein and gene sequences. We summarize the advances in antiviral therapy with the SARS-CoV-2 vaccine and extracellular vesicles via computational analysis.

show abstract

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine

Cited by 3 publications

References 24 publications

Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients

Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients

SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort

In Silico Protein Structure Analysis for SARS-CoV-2 Vaccines Using Deep Learning

Contact Info

Product

Resources

About